Neoplasms

Mouth and Tooth Diseases

Ear, Nose, and Throat Diseases

All Conditions

Rare Diseases

Nasopharyngeal Carcinoma

Carcinoma

Acute Graft Versus Host Disease

The dose of lobaplatin is 25mg/m2 on d1,d22,d43.

The dose of lobaplatin is 40mg/m2 on d1,d22,d43.

The dose of lobaplatin is 45mg/m2 on d1,d22,d43.

The dose of lobaplatin is 50mg/m2 on d1,d22,d43.

Lobaplatin

linear accelerator

Siyang Wang, bachelor

Nasopharyngeal carcinoma (NPC) is a common malignant tumor in Southern China area, which is characterized by obvious regional characteristics and "Guangdong cancer". Radiotherapy is the main treatment for locally advanced nasopharyngeal carcinoma. In recent years, chemotherapy has improved the short-term and long-term survival of patients with locally advanced nasopharyngeal carcinoma.

Lobaplatin is the third generation platinum anticancer drugs, mechanism of action and traditional cisplatin is similar, mainly formed by the Pt-GG and Pt-AG chain cross connect, replication and transcription process blocks of deoxyribonucleic acid(DNA), thereby interfering with tumor cell cycle. The damage of DNA induced by lobaplatin can influence the expression of tumor cell specific genes. Due to the different structure of lobaplatin and no cross resistance to cisplatin in the study showed that, compared with cisplatin with gastrointestinal reaction more mild, and no cisplatin common liver and kidney toxicity, neurotoxicity and ototoxicity, in some tumors have a better adaptability; but compared with cisplatin had more severe bone marrow suppression this, offset some of the advantages of lobaplatin in a certain extent. At present, the clinical indications for the treatment of such diseases include head and neck cancer, breast cancer, gastrointestinal cancer, gynecologic malignant tumor and non small cell lung cancer. Tian Ying confirmed that lobaplatin has obvious cytotoxic effect on nasopharyngeal carcinoma cells, in a concentration dependent manner, the mechanism for the dual role, namely block at lower concentration of cells in G2 phase and induce apoptosis at higher concentration, provide the possibility for clinical treatment of nasopharyngeal carcinoma for lobaplatin; there are a number of clinical study confirmed that lobaplatin chemoradiotherapy for locally advanced nasopharyngeal carcinoma with cisplatin approximation. But at present, there is no report on the dose and tolerability of concurrent radiotherapy for nasopharyngeal carcinoma.

Therefore, a dose escalation trial was conducted to determine maximum tolerated dose of lobaplat in as a single agent combined with concurrent intensity-modulated radiotherapy in a Chinese population with locoregionally advanced NPC.

The initial dose was 25mg/m2 on d1,d22,d43 for 1 cycles; if no obvious toxicity was observed,follow 30mg/m2,35mg/m2,40mg/m2,45mg/m2, and 50mg/m2 gradients into the next dose group until the maximum tolerated dose or 50mg/m2

Dose Escalation of Lobaplatin Concurrent With IMRT for the Treatment of NPC: A Phase I Clinical Trial

Dose Escalation of Lobaplatin Concurrent With Intensity-modulated Radiotherapy for the Treatment of Stage III-IVb Nasopharyngeal Carcinoma: A Phase I Clinical Trial in an Asian Population

ALT: grade 3: \> 5.0-20.0\*ULN; grade 4: \> 20.0\*ULN.

grade 3: \> 5.0-20.0\*ULN; grade 4: \> 20.0\*ULN.

grade 3: \> 3.0-10.0\*ULN; grade 4: \> 10.0\*ULN.

grade 3:\> 5.0-20.0\*ULN; grade 4: \> 20.0\*ULN.

grade 3: \> 3.0-6.0\*ULN, \> 3.0 baseline; grade 4: \> 6.0\*ULN.

grade 3: 25.0-\< 50.0\*109/L; grade 4:\< 25.0\*109/L.

grade 3: 1.0-\< 2.0\*10\^9/L; grade 4: \< 1.0\*10\^9/L.

grade 3: 0.5-\< 1.0\*10\^9/L; grade 4: \< 0.5\*10\^9/L.

grade 3: \< 80 g/L; transfusion indicated; grade 4:Life-threatening consequences; urgent intervention indicated; grade 5: Death

grade 3: Inadequate oral caloric or fluid intake; tube feeding, TPN, or hospitalization indicated

grade 3: \> 6 episodes (separated by 5 minutes) in 24 hrs; tube feeding, TPN, or hospitalization indicated; grade 4:Life-threatening consequences; urgent intervention indicated; grade 5: Death.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Dose Escalation of Lobaplatin Concurrent With IMRT for the Treatment of NPC: A Phase I Clinical Trial	NCT03188497	Acute Toxic Eff... Tumor Responses	Lobaplatin linear accelera...	18 Years - 65 Years	Fifth Affiliated Hospital, Sun Yat-Sen University
Dose Escalation of Lobaplatin Concurrent With IMRT for the Treatment of NPC: A Phase I Clinical Trial	NCT03188497	Acute Toxic Eff... Tumor Responses	Lobaplatin linear accelera...	18 Years - 65 Years	Fifth Affiliated Hospital, Sun Yat-Sen University

Spots Global Cancer Trial Database for tumor responses